Ozmosi | Arotinolol Drug Profile

Product Description

Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Arotinolol)

Mechanisms of Action: ADRB Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Beijing Huasu Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Kidney Failure, Chronic|Hypertension

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT06780865	PRECISE	N/A	Not yet recruiting	Hypertension, Renal\|Kidney Failure, Chronic	2028-12-31	2025-01-18	Primary Endpoints\|Treatments
CTR20253299	CTR20253299	N/A	Completed	Tachycardia\|Essential Tremor\|Angina Pectoris\|Hypertension	2025-10-26	2026-01-11	Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20250259	CTR20250259	N/A	Completed	Angina Pectoris\|Essential Tremor\|Tachycardia\|Hypertension	2025-05-07	2025-05-11	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date
CTR20250187	CTR20250187	N/A	Completed	Tachycardia\|Hypertension\|Angina Pectoris\|Essential Tremor	2025-04-20	2025-05-11	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20244971	CTR20244971	N/A	Completed	Tachycardia\|Hypertension\|Angina Pectoris\|Essential Tremor	2025-04-14	2025-05-04	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20240291	CTR20240291	N/A	Completed	Essential Tremor\|Hypertension\|Tachycardia\|Angina Pectoris	2024-05-14	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20233688	CTR20233688	N/A	Completed	Angina Pectoris\|Tachycardia\|Essential Tremor\|Hypertension	2024-01-10	2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20231657	CTR20231657	N/A	Completed	Essential Tremor\|Angina Pectoris\|Hypertension\|Tachycardia	2023-07-16	2025-04-29	Patient Enrollment\|Treatments
CTR20231103	CTR20231103	N/A	Completed	Essential Tremor\|Angina Pectoris\|Tachycardia\|Hypertension	2023-06-02	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
ChiCTR2100049628	ChiCTR2100049628	N/A	Not yet recruiting	Hypertension	2022-12-31
CTR20213148	CTR20213148	N/A	Completed	Angina Pectoris\|Essential Tremor\|Tachycardia\|Hypertension	2021-12-14	2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20211285	CTR20211285	N/A	Completed	Essential Tremor\|Hypertension\|Angina Pectoris\|Tachycardia	2021-08-18	2025-04-29	Patient Enrollment\|Treatments
CTR20210372	CTR20210372	N/A	Completed	Angina Pectoris\|Hypertension\|Tachycardia\|Essential Tremor	2021-03-18	2025-04-29	Patient Enrollment\|Treatments
ChiCTR-TQR-12002674	ChiCTR-TQR-12002674	N/A	Recruiting	Hypertension	2016-12-31
ChiCTR-TRC-14004132	ChiCTR-TRC-14004132	N/A	Completed	Hypertension	2015-12-31
ChiCTR1900021852	AHOCEP	N/A	Completed	Kidney Diseases\|Hypertension, Renal	2015-06-30
CTR20244148	CTR20244148	N/A	Terminated	Angina Pectoris\|Tachycardia\|Hypertension\|Essential Tremor	None	2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
CTR20243794	CTR20243794	N/A	Terminated	Essential Tremor\|Angina Pectoris\|Hypertension\|Tachycardia	None	2025-04-29	Patient Enrollment\|Treatments\|Trial Status
CTR20233174	CTR20233174	N/A	Recruiting	Hypertension\|Tachycardia\|Essential Tremor\|Angina Pectoris	None	2025-04-29	Patient Enrollment\|Start Date\|Treatments\|Trial Status
NCT01351636	AHOCEP	P4	Completed	Kidney Failure, Chronic	2018-10-10	2022-07-22	Primary Endpoints\|Treatments
NCT02612298	ESAHOM	P4	Completed	Hypertension	2018-09-13	2022-07-22	Primary Endpoints

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Arotinolol

Alternative Names: arotinolol Clinical Status: Inactive Latest Update: 2025-01-17 Latest Update Note: Clinical Trial Update